07 Feb News from Norway
The Norwegian Medicines Agency has recently announced a need for more suppliers or alternatives on the market in Norway for the active substances ivermectin and erythromycin, and want to get in contact with possible suppliers.
The Norwegian Medicines Agency’s announcement list are applicable for medicinal products deemed as critical to the market, with regard to public health. Possible reasons for shortage could be withdrawal, cease of marketing or vulnerable supply. The Norwegian Medicines Agency may evaluate reduced requirements/fees on a case-by-case basis for the products on the announcement list.
If you need support with applications or advice in regard to national procedures and requirements, please contact us in www.mericon.no
Please follow the link to find more information and the detailed list of applicable medicinal products: